LIPERIAL Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

liperial

viatris healthcare limited - fenofibrato - fenofibrato

FASTJEKT Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

fastjekt

viatris healthcare limited - adrenalina - adrenalina

FEVARIN Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

fevarin

viatris healthcare limited - fluvoxamina - fluvoxamina

INFLUVAC S TETRA Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

influvac s tetra

viatris healthcare limited - influenza, antigene purificato - influenza, antigene purificato

TOVASTIBE Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

tovastibe

viatris healthcare limited - atorvastatina e ezetimibe - atorvastatina e ezetimibe

IDIPULFIB Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

idipulfib

viatris healthcare limited - pirfenidone - pirfenidone

TERIPARATIDE VIATRIS Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

teriparatide viatris

viatris healthcare limited - teriparatide - teriparatide

Rivaroxaban Viatris (previously Rivaroxaban Mylan) Európai Unió - olasz - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agenti antitrombotici - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

MUSE Olaszország - olasz - AIFA (Agenzia Italiana del Farmaco)

muse

viatris healthcare limited - alprostadil - alprostadil